Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 1:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 203 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: THC Clear all
Terminated Phase 1 Interventional

Dronabinol for Pain and Inflammation in Adults Living With Sickle Cell Disease

NCT03978156
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Dronabinol 2.5 MG, Microcrystalline cellulose
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Dronabinol Capsules 10 mg Under Fasting Conditions

NCT01380457
View directory record Official record
Conditions
To Determine Bioequivalence Under Fasting Conditions
Interventions
Dronabinol, Marinol
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2011 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease

NCT02792257
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dronabinol (Marinol®), Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
60 Years to 95 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
5
States / cities
Miami, Florida • Baltimore, Maryland • Belmont, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache

NCT00123201
View directory record Official record
Conditions
Migraine With Aura, Migraine Without Aura
Interventions
Dronabinol MDI
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
29
States / cities
Huntsville, Alabama • Tucson, Arizona • Anaheim, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

The Effects of ∆-9-THC and Naloxone in Humans

NCT01591629
View directory record Official record
Conditions
Healthy
Interventions
Naloxone, Delta-9-THC, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 20, 2026, 1:52 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessing Claims of Cannabis as an Anti-cancer Agent (CATA)

NCT07107607
View directory record Official record
Conditions
Cancer, Cancer (With or Without Metastasis)
Interventions
Not listed
Lead sponsor
HealthPartners Institute
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.

NCT00278954
View directory record Official record
Conditions
Primary Immunodeficiency, Common Variable Hypogammaglobulinemia, X-linked Hypogammaglobulinemia, Hypogammaglobulinemia, Immunodeficiency With Hyper-IgM, Wiskott-Aldrich Syndrome
Interventions
Gammaplex (Intravenous immunoglobulin)
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
3 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
North Palm Beach, Florida • Atlanta, Georgia • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced Oct 20, 2026, 1:52 PM EDT
Recruiting Early Phase 1 Interventional

Effects of Dronabinol in Opioid Maintained Patients

NCT04025359
View directory record Official record
Conditions
Pain
Interventions
Dronabinol, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 70 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Dronabinol (Oral THC) on Cannabis Use

NCT01394185
View directory record Official record
Conditions
Marijuana Smoking
Interventions
Dronabinol 120mg/day, Placebo, Dronabinol 240mg/day
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 3, 2017 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of the Safety and Efficacy of Four Different Potencies of Smoked Marijuana in 76 Veterans With PTSD

NCT02759185
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
High THC cannabis, High CBD cannabis, THC/CBD cannabis, Placebo cannabis
Drug
Lead sponsor
Multidisciplinary Association for Psychedelic Studies
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 12, 2023 · Synced Oct 20, 2026, 1:52 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Responses to Marijuana-Related Cues Versus Neutral Cues in Adults Taking Tetrahydrocannabinol (THC) - 2

NCT00218504
View directory record Official record
Conditions
Marijuana Abuse
Interventions
Tetrahydrocannabinol
Drug
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Early Phase 1 Interventional Results available

Dronabinol Interactions With Cognitive Enhancing Drug in Humans

NCT00842985
View directory record Official record
Conditions
Cannabis, Marijuana Abuse
Interventions
drug condition
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 4 Interventional Results available

A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

NCT01289847
View directory record Official record
Conditions
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Hyper-IgM Syndrome, Wiskott-Aldrich Syndrome
Interventions
Gammaplex
Biological
Lead sponsor
Bio Products Laboratory
Other
Eligibility
2 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Irvine, California • Los Angeles, California • Centennial, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 20, 2026, 1:52 PM EDT
Completed No phase listed Observational

Study of Megakaryocytes From Patients With Abnormal Platelet Vesicles

NCT00086476
View directory record Official record
Conditions
Blood Coagulation Disorders
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal

NCT00480441
View directory record Official record
Conditions
Marijuana Dependence
Interventions
Dronabinol, BRENDA therapy, Placebo
Drug · Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Delta-9-THC and Iomazenil in Healthy Humans

NCT00982982
View directory record Official record
Conditions
Schizophrenia, Mental Disorders, Psychotic Disorders
Interventions
THC and Iomazenil, Placebo (control)
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years · Male only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Motivation and Skills for Delta-9-tetrahydrocannabinol/Ethanol (THC/ETOH+) Teens in Jail

NCT00506753
View directory record Official record
Conditions
Alcohol Drinking, Marijuana Smoking
Interventions
MI/CBT, RT/SU
Behavioral
Lead sponsor
University of Rhode Island
Other
Eligibility
14 Years to 19 Years
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Cranston, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 1 Interventional

Effects of Delta9-tetrahydrocannabinol (THC) on Retention of Memory for Fear Extinction Learning in PTSD: R33 Study

NCT04080427
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Placebo capsule, Dronabinol 7.5 milligram oral capsule
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 60 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 20, 2026, 1:52 PM EDT
Withdrawn Phase 2 Interventional

The Safety, Tolerability and Efficacy of Dronabinol, for the Treatment of Nausea and Vomiting in Familial Dysautonomia

NCT02608931
View directory record Official record
Conditions
Nausea, Vomiting, Familial Dysautonomia
Interventions
Dronabinol, Placebo
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 20, 2026, 1:52 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Behavioral and Physiological Effects of THC and CBD

NCT03832816
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, Vaporized THC alone, Vaporized CBD alone, Vaporized CBD with THC
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Oct 20, 2026, 1:52 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of Dronabinol to Treat Obstructive Sleep Apnea

NCT01755091
View directory record Official record
Conditions
Sleep Apnea, Obstructive
Interventions
Dronabinol, Placebo (for Dronabinol)
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
21 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Oct 20, 2026, 1:52 PM EDT
Withdrawn Phase 2 Interventional

Dronabinol As an Adjunct for Reducing Pain (DARP)-Texas Children's Hospital

NCT06834997
View directory record Official record
Conditions
Endometriosis, Endometriosis Related Pain, Endometriosis, Pain
Interventions
Dronabinol Capsules, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Hosuton, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 20, 2026, 1:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

NCT01832766
View directory record Official record
Conditions
Schizophrenia
Interventions
Dronabinol, Placebo Comparator
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Oct 20, 2026, 1:52 PM EDT
Completed No phase listed Observational

Participation in a Research Registry for Immune Disorders

NCT01953016
View directory record Official record
Conditions
Primary Immunodeficiencies, APECED, CGD, Wiskott-Aldrich Syndrome, SCID
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 20, 2026, 1:52 PM EDT